
Flamel Technologies SA ( FLML ) Q1 2012 Earnings Call May 7, 2012 8:30 am ET Executives Michael Anderson – Chief Executive Officer Sian Crouzet – Principal
s not so surprising. After all, other drug development names like Nektar ( NKTR ), PDL BioPharma ( PDLI ), and Flamel ( FLML ) really haven't worked out to early expectations. Things are different now. Not only does the company have a mature portfolio
Flamel Technologies S.A. ( FLML ) Q4 2011 Earnings Conference Call March 15, 2012 8:30 AM ET Executives Stephen Willard – Director Mike Anderson – CEO Siân Crouzet
Flamel Technologies ( FLML ) -19% premarket after agreeing to acquire specialty drug maker Eclat Pharmaceuticals in a debt-and-warrant deal and named Eclat's chief executive to replace its own CEO. Post your comment!
Flamel Technologies S.A ( FLML ) Q3 2011 Earnings Call November 3, 2011 08:30 am ET Executives Stephen Willard - CEO, CFO and General Counsel Siân Crouzet
Flamel Technologies S.A. ( FLML ) Q1 2011 Earnings Call May 9, 2011 8:30 a.m. ET Executives Stephen Willard – CEO Siân Crouzet – Principal Financial Officer
Good morning, ladies and gentlemen and welcome to the Flamel Technologies First Quarter Conference Call. After prepared remarks, we will be opening the call to a question-and-answer period. As a reminder, this call is being recorded. At this time, it is my pleasure to turn the conference over to ...
Flamel Technologies S.A. ( FLML ) Q4 2010 Earnings Conference Call March 4, 2011, 8:30 am ET Executives Stephen Willard – CEO Siân Crouzet – Principal Financial
We're keeping our fair value estimate intact after reviewing the recent progress of Flamel Technologies' FLML pipeline. Since May, Flamel has added three new partnership agreements with two of its pharmaceutical partners to its feasibility
We're maintaining our fair value estimate after reviewing Flamel Technologies' FLML progress throughout 2009 . The firm continued to make headway in persuading larger drugmakers to try out its Medusa technology